Felony Charges Against 3 in Utah Related to Stem Cells, Undercover Agents Visited Clinic
Utah authorities have filed felony charges against Dr. Paul William Winterton, Randall Matthew Relyea, and Jenny Astrid Fraizer for a pattern of unlawful activity at the Precision Pointe Regenerative Health clinic. The indictments include second‑degree felonies for communications fraud, third‑degree felonies for obstruction of justice, and multiple counts of unlawful practice of osteopathic medicine. Undercover agents reportedly visited the clinic, uncovering procedures performed without anesthetic and other violations. The case emerges amid a new Utah law permitting certain non‑FDA‑approved stem‑cell injections, raising regulatory complexities.
A DIY, Fly-Powered Food Waste Recycling System
University of California‑Riverside researchers have engineered a DIY black‑soldier fly bioreactor that converts on‑site food waste into high‑protein larvae and nutrient‑dense frass. The system uses off‑the‑shelf materials, operates under a single caretaker, and yields roughly one pound of larvae per...
Accelerated Cancer Drug Approvals Deliver Limited Survival Gains at High Cost
A BMJ Medicine study examined Medicare’s use of FDA accelerated‑approval cancer drugs from 2012‑2020. Of the 178,000 beneficiaries treated, only 45% received drugs that later proved to extend survival, adding an estimated 76,000 life‑years. The three most beneficial drugs accounted...
The FDA’s Proposed “Black Box” Warning for COVID-19 Vaccines
Former FDA official Henry I. Miller warns that the agency’s draft plan to place a black‑box warning on COVID‑19 vaccines lacks scientific justification. He notes that the proposal appears driven by political appointees, particularly HHS Secretary Robert F. Kennedy Jr., rather than robust...
A Year of Biotech Bytes: The Stories, Lessons, and Laughs Behind the Mic
In this retrospective episode, host and guest Mary Louise Smith reflect on Biotech Bytes' first year, sharing how the podcast began, the power of simple conversations for generating ideas, and the role of AI in streamlining work. Mary offers behind‑the‑scenes...
New Microfluidics Technology Enables Highly Uniform DNA Condensate Formation
Researchers at Chuo University introduced a vibration‑induced local vortex (VILV) platform that creates highly uniform DNA condensate droplets using a low‑cost piezoelectric vibrator. The system replaces traditional microfluidic pumps with stable micro‑vortex arrays generated on a simple micropillar device, enabling...
Gepotidacin
Gepotidacin (Blujepa®), an oral bacterial type II topoisomerase inhibitor developed by GSK, received approval in April 2025 for uncomplicated urinary‑tract infections and gonorrhea. The drug emerged from an unbiased antibacterial screening program and represents the first new oral class of antibiotics targeting...
Artificial Metabolism Turns Waste CO₂ Into Useful Chemicals
Northwestern and Stanford researchers have engineered a fully synthetic, cell‑free metabolism called the Reductive Formate Pathway (ReForm) that converts CO₂‑derived formate into acetyl‑CoA and subsequently into malate, a high‑value chemical. The pathway relies on five engineered enzymes arranged in six...
Tiny Viral Switch Offers Hope Against Drug-Resistant Bacteria
Researchers at Hebrew University identified a tiny phage‑encoded RNA, PreS, that reprograms bacterial host cells during infection. PreS binds to the folded region of the bacterial dnaN mRNA, unfolding it and boosting production of the DnaN replication protein. The resulting...
844: Applying Physics and Nanotechnology to Understand Mechanics and Shape in Biological Systems - Dr. Sonia Contera
In this episode, Dr. Sonia Contera discusses how physics and nanotechnology can illuminate the mechanics and shape of biological systems, from molecular assemblies to whole organs. She explains her interdisciplinary approaches—such as nanoscale imaging and mechanical probing—to study pancreatic tumors,...
Every Accusation Is a Confession (or a Statement of Intent): MAHA’s New Tuskegee Experiment
The U.S. Centers for Disease Control and Prevention awarded a $1.6 million grant to the University of Southern Denmark to conduct a five‑year randomized trial of hepatitis B vaccine timing in newborns in Guinea‑Bissau. The study, led by Christine Stabell Benn and Peter Aaby,...
Weekly Reads: Stem Cells for Vision Loss Hope, Gene Therapy Trial Death, NFL Doc on Clinics
A low‑dose adult stem‑cell transplant (RPESC‑RPE‑4W) for dry age‑related macular degeneration met primary safety endpoints and showed visual acuity gains. In a separate development, a child died during a pioneering gene‑therapy trial that used engineered viruses to cross the blood‑brain...
Brinsupri Setback Slices Insmed Market Cap — Clinical Report
Insmed’s experimental therapy Brinsupri failed to meet its primary efficacy endpoint in a Phase 2 trial involving 150 patients with rare lung disease, triggering a sharp market reaction. The company announced the setback on Dec. 19, 2025, and its market...
A Non-Profit Brought an Abandoned Rare Disease Gene Therapy to Market. Can the Model Scale?
A non‑profit, Fondazione Telethon, partnered with a U.S. charity to bring a lentiviral stem‑cell gene therapy for Wiskott‑Aldrich syndrome to market. The FDA approved the product, Waskyra etuvetidigene autotemcel, marking the first time a non‑profit acted as the regulatory applicant. The therapy...
Raising the Sun: Japan Biotech Looks to Level Up
Japan’s biotech industry is entering a growth phase as the government unveils a ¥200 billion fund and regulatory sandbox to speed drug development. Venture capital activity surged 45% year‑over‑year, fueling a wave of startups focused on gene therapy and rare‑disease platforms....
Seeking ‘Continuous’ Run of Deals, BioMarin Adds Fabry, Pompe Drugs via $4.8B Amicus Takeout
BioMarin Pharmaceutical announced a $4.8 billion acquisition of Amicus Therapeutics, a move designed to fuel a continuous stream of strategic deals. The transaction will bring two marketed orphan drugs—one for Fabry disease and another for Pompe disease—into BioMarin’s portfolio, together projected...
Cai Succeeding Zhang as Head of CSPC
Cai has been appointed to replace Zhang as head of China Starch & Pharmaceutical Co. (CSPC), the country’s largest generic drug manufacturer. The transition was announced in December 2025 and is effective immediately. Cai brings a background in AI-driven drug...
November 2025 Patent Highlights
The November 2025 Patent Highlights post serves as a gateway to Drug Hunter’s most‑read resources, including top‑10 lists of popular articles, reviews, and case studies from the year. It spotlights a detailed review of FcRn biology and the push toward oral...
U.S. Vaccine Approvals to Undergo Overhaul: What Do the Changes Mean?
The U.S. FDA has disclosed a draft overhaul that would tighten vaccine approval standards, requiring developers to submit expanded safety and efficacy data and potentially subject annual flu shots to large‑scale trials. Simultaneously, the CDC withdrew its universal hepatitis B vaccination...
Johnson & Johnson’s Hematology Portfolio: Breakthroughs to Watch
Johnson & Johnson showcased a robust hematology pipeline at the ASH 2025 meeting, unveiling more than 60 new abstracts. The company highlighted real‑world evidence from thousands of patients, underscoring the efficacy of its CAR‑T, bispecific and gene‑editing therapies. Notably, the...
NU-9 Halts Alzheimer's Disease in Animal Model Before Symptoms Begin
Northwestern researchers report that the small‑molecule NU‑9 eliminates a newly identified toxic amyloid‑beta oligomer subtype in a pre‑symptomatic mouse model of Alzheimer’s disease. Daily oral administration for 60 days dramatically reduced reactive astrogliosis, neuroinflammation, and associated TDP‑43 pathology across multiple...
Using AI In Patent Practice: Practical and Ethical Issues
At the BIO International Convention’s IP Counsels Committee panel, experts outlined how AI is reshaping patent practice. They classified tools into traditional, generative, and patent‑specific solutions, stressing secure enterprise versions for confidential data. Ethical pitfalls—including AI hallucinations and potential public...
Dr. Vinay Prasad “Called For” RCTs. Dr. Peter Marks Delivered Them.
Dr. Vinay Prasad claims he was among the few who called for randomized controlled trials (RCTs) of COVID‑19 vaccines, yet the blog argues that it was his predecessor, Dr. Peter Marks, who actually designed and executed the pivotal trials that...
GLP Podcast: Evolutionary Mismatch. Is Civilization Wrecking Our Health?
The episode examines the evolutionary mismatch theory, arguing that modern industrialized life bombards humans with chronic low‑level stressors unlike the intermittent challenges faced by our hunter‑gatherer ancestors, leading to physical ailments such as hypertension, immune decline, and reduced fertility, as...
Stelios Papadopoulos Brings the Long View on Biotech on The BioCentury Show
Stelios Papadopoulos, former Biogen chair and current Exelixis leader, warned that biotech faces heightened pricing pressure and rising competition from China despite a surge of over $3 billion in capital in a single day. He argued that the sector can no...
How Alphamab Is Differentiating in Crowded Cancer Targets
Alphamab is launching a next‑generation bispecific antibody‑drug conjugate (ADC) platform that simultaneously engages two tumor antigens while employing a lower drug‑to‑antibody ratio (DAR). The company argues that this design improves the therapeutic index by delivering potent payloads more selectively and...
Third Rock Backs Steve Paul’s Latest Schizophrenia Spinout in $165M Round: Venture Report
Third Rock Ventures led a $165 million financing round for Steve Paul’s newest schizophrenia‑focused biotech, marking a significant venture capital commitment to neuropsychiatric innovation. Paul, a serial biotech founder, will use the capital to move novel mechanisms from discovery into early...
Early Signals Stack Up: Two Small Molecules Activate GCase in Parkinson’s
Gain Therapeutics reported Phase Ib data showing that its small‑molecule program reduces glucosylceramide substrate in the central nervous system, confirming target engagement of glucocerebrosidase (GCase). In parallel, Vanqua Bio presented early evidence that its distinct compound activates peripheral GCase while...
Induced Pluripotent Stem Cells: From Dish to Freezer and Back
Kobe University researchers have devised a cryopreservation protocol that freezes induced pluripotent stem cells (iPSCs) directly in their 2‑dimensional culture dishes. The method uses the inexpensive amino acid D‑proline combined with a synthetic polymer and a brief enzymatic step to...
Editors’ Choice: Top Stories of 2025
In the year‑end episode, GEN editors review six headline biotech stories, highlighting AI’s expanding role in drug discovery, a landmark success for Baby KJ in cell‑gene therapy, and the turbulent year for Sarepta’s DMD gene therapy Elevidys, including patient deaths...
GOP Lawmakers Ask RFK Jr. To Make FDA Unleash Risky Peptides Like BPC-157
GOP Representative Diana Harshbarger, a pharmacist, wrote FDA Commissioner RFK Jr. urging the agency to use enforcement discretion to loosen restrictions on six unapproved wellness peptides, including BPC‑157 and CJC‑1295. The request echoes a similar appeal from Senator Tommy Tuberville, signaling...
Spray-On Antibacterial Coating Offers New Protection for Plants Against Disease and Drought
UC San Diego engineers have created a water‑based spray polymer coating that shields plant leaves from bacterial infection and improves drought tolerance. The polynorbornene polymer carries positive charges that disrupt bacterial membranes while remaining gas‑permeable for normal leaf respiration. Laboratory...
Targeting NLRP3: DFV890 and Beyond
The article reviews the NLRP3 inflammasome inhibitor DFV890, highlighting its Phase 2 data in acute coronary syndrome and its mechanism of selectively blocking NLRP3 activation. It also examines emerging NLRP3‑targeted programs, including covalent inhibitors and PROTAC degraders, and discusses the broader...
ALS and the Market for False Hope
The post outlines ALS as a progressive neurodegenerative disease with no cure and only modestly effective drugs such as riluzole and edaravone. It highlights how multidisciplinary ALS clinics deliver the greatest survival benefit, while a booming market of unproven supplements...
Researchers Co-Develop New Deep Learning Platform to Advance Precision Medicine
Researchers from Marshall University and the University of Missouri unveiled G2PDeep, a web‑based deep‑learning platform that fuses six major omics data streams to predict complex health outcomes. The peer‑reviewed study in *Biomolecules* demonstrates the tool’s ability to identify molecular markers,...
The Antibiotic Delafloxacin Emerges as a Potential Therapeutic Alternative Against Legionella
Researchers at the IGTP demonstrated that delafloxacin inhibits intracellular Legionella replication more effectively than levofloxacin in a macrophage model. The fluoroquinolone achieved bacterial killing at concentrations five to ten times lower than the current standard, except for L. longbeachae where...
New Role for Tam Man Hong at Xtalpi
Xtalpi announced that veteran biotech executive Tam Man Hong will assume the role of President, Business Development, effective immediately. The appointment comes as the company finalizes a $150 million Series B financing round to expand its AI‑driven protein therapeutics platform. Hong, who...
Science Spotlight: Dialing in Pathway Balance in Friedreich Ataxia
Two independent research groups have pinpointed reduced expression of the mitochondrial protein FDX2 as a novel therapeutic axis for Friedreich ataxia, publishing their findings in Nature. The studies argue that frataxin (FXN) and FDX2 function as a stoichiometric pair, and...
Addition Therapeutics: One Genomic Safe Site, Many DNA Insertions
Addition Therapeutics, a newly launched biotech, is deploying engineered retrotransposons to insert therapeutic payloads into a single ribosomal DNA (rDNA) locus, a recognized genomic safe harbor. By concentrating multiple genes at this highly transcribed, repetitive site, the platform promises stable...
Mirdametinib (PD0325901)
Springworks Therapeutics and Pfizer announced FDA approval of mirdametinib (PD0325901), an oral, brain‑penetrant MEK1/2 inhibitor for treating neurofibromatosis type 1‑associated plexiform neurofibromas (NF1‑PN) in both adults and children. The drug was optimized from an earlier in‑vitro tool compound to improve potency...
Eight of the Biggest Immunology and Inflammation (I&I) Deals in 2025
In 2025 the immunology and inflammation sector saw eight blockbuster partnerships, each worth between $1.7 billion and $4 billion. Deals ranged from AstraZeneca’s $175 million upfront, $4.4 billion‑potential collaboration with Harbour BioMed to Vor Bio’s surprising $4 billion licensing of telitacicept despite a massive wind‑down....
Accelerating Drug Combination Discovery with Machine Learning
St. Jude researchers unveiled Combocat, an open‑source platform that merges acoustic liquid handling with machine‑learning models to screen drug combinations at unprecedented scale. The system tested 9,045 drug pairs on a neuroblastoma cell line, identifying multiple synergistic hits that were...
BIO IP Conference Looks at Academics and Perceptions of IP
The BIO IP Counsel Committee Conference addressed growing skepticism toward patents in biopharma, amplified by pandemic‑era messaging that frames IP as a barrier to care. Panelists argued that patents remain vital incentives for costly research and development, despite public concerns...
Patient Advocates Urge Action on PPRV to Help Fight Rare Disease
Patient advocates at BIO’s December Coffee Chat urged Congress to reauthorize the Pediatric Priority Review Voucher (PPRV) program before year‑end. The voucher scheme, which expired in 2024, has awarded 63 vouchers for 47 rare pediatric diseases, turning four treated conditions...
Weekly TechBio News
The episode highlights four major tech‑bio developments: LatchBio’s launch of agent.bio, an interactive sandbox for spatial biology analysis across five platforms; Chai Discovery’s $130 M Series B raise to build an AI‑driven CAD suite for drug design, backed by OpenAI; Accenture Ventures’...
RTW Leans Into NewCo Model with GenSci Deal for Ocular Autoimmune Therapy: Deals Report
RTW Therapeutics announced a strategic partnership with GenSci to form a new joint‑venture focused on developing an ocular autoimmune therapy. The collaboration adopts a NewCo model, with both parties contributing capital and expertise to accelerate drug discovery for non‑infectious uveitis....
The Evolving BTK Story in Multiple Sclerosis: Clinical Report
Sanofi’s Bruton’s tyrosine kinase (BTK) inhibitor failed to meet its primary endpoint in a pivotal trial for primary progressive multiple sclerosis, while the company awaits an FDA decision on a secondary progressive indication. Roche, meanwhile, reported encouraging efficacy and safety...
Measuring Drug Target Success
The episode explores how drug targets are identified and validated, highlighting genetic, animal, and in‑vitro evidence as key sources. It discusses the limited predictive power of pre‑clinical data, noting that genetically validated targets double the odds of clinical success while...
$12B-Plus in New Life Sciences Funds This Year
Venture capital activity in life sciences has surged in 2025, with at least 27 firms announcing new funds. Collectively, these vehicles have attracted more than $12 billion in capital, marking a record inflow for the sector. Notably, four of the funds...
Who Invented What? BIO IP Panel Tackles Joint Inventorship
The BIO IP panel highlighted that joint inventorship is now the norm in biotech, replacing the lone‑inventor myth. It outlined the legal elements—conception, collaboration, corroboration—and illustrated them with real and hypothetical cases, including AI‑driven research. Panelists warned that mis‑attributing inventors...